CELZ Latest Press Releases

-- October 20, 2026 --

Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome Knee Osteoarthritis Study Globe Newswire 9:15 AM

-- September 17, 2026 --

Creative Medical Technology Holdings, Inc. Expands Ultrasome Intellectual Property Portfolio with New U.S. Provisional Patent Filing Globe Newswire 9:00 AM

-- August 20, 2026 --

Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning Globe Newswire 9:15 AM

-- August 6, 2026 --

Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz , CELZ-101 and CELZ-201 Diabetes Platforms Globe Newswire 9:15 AM

-- July 1, 2026 --

Creative Medical Technology Holdings Issues Mid-Year Update Globe Newswire 9:00 AM

-- June 30, 2026 --

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds Globe Newswire 2:07 PM

-- June 22, 2026 --

Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain Globe Newswire 9:15 AM

-- June 16, 2026 --

Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards Globe Newswire 9:00 AM

Market Data Delayed 15 Minutes